FISH检测乳腺癌HER2基因扩增及临床病理关系的研究

目的：探讨荧光原位杂交（FISH）检测原发性乳腺癌组织中HER2基因扩增与临床病理的关系。方法：收集2007年11月至2009年8月手术切除的乳腺癌组织标本105例,采用FISH方法检测HER2基因扩增情况,分析其与临床病理的关系,同时比较FISH与免疫组化（IHC）检测结果的相关性。结果：105例乳腺癌中共有39例HER2基因扩增,阳性率为37.1%（39/105）,其扩增与HER2蛋白过表达、组织学分级、雌激素和孕激素受体（均P〈0.05）状态有关;FISH与IHC两种方法检测HER2结果密切相关（rs=0.680,P〈0.05）。结论：HER2基因扩增与乳腺癌发生发展及临床预后密切相关,可作为乳腺癌治疗的理想靶点。

RELATIONSHIP BETWEEN HER2 ONCOGENE AMPLIFICATION BY FLUORESCENCE IN SITU HYBRIDIZATION AND CLINICAL PATHOLOGY OF BREAST CANCER

Objective：To study the relationship between HER2 oncogene amplification by fluorescence in situ hybridization and clinical pathology of breast cancer.Methods：The fluorescence in situ hybridization was used to detect HER2 oncogene amplification in 105 cases with breast cancer between November 2007 and August 2009,and the correlation with the clinical pathology was evaluated.The difference of FISH and IHC was compared.Results：Thirty-nine cases were HER2 gene amplification in 105 cases of breast cancer and the positive rate was 37.1%.HER2 gene amplification was correlated with HER2 protein expression（P〈0.05）,histological grade（P〈0.05）,estrogen receptor（P〈0.05） and progesterone receptor（P〈0.05）status.HER2 results were significant correlated to FISH and IHC（rs=0.680,P〈0.05）.Conclusion：The data show that the gene amplification of HER2 was closely related to the occurrence-development and clinical prognosis of breast cancer,and can be used as an ideal target for the treatment of breast cancer.